Acadia Pharmaceuticals has been granted a patent for a method to treat Prader-Willi Syndrome (PWS) by regulating prohormone convertase (PC1) levels. The method involves administering a selective phosphodiesterase 4 inhibitor (PDE4i) to alleviate symptoms of PWS. GlobalData’s report on Acadia Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Acadia Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Acadia Pharmaceuticals's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Treating prader-willi syndrome with pde4 inhibitor
A recently granted patent (Publication Number: US11957656B2) discloses a method for treating Prader-Willi Syndrome (PWS) by administering a selective phosphodiesterase 4 inhibitor (PDE4i) to individuals with PWS. The method aims to alleviate, eliminate, or prevent various symptoms associated with PWS, such as hyperphagia, reduced metabolic rate, obesity, hypogonadism, and impaired cognition. The patent claims also include the administration of additional therapeutic agents effective in treating PWS symptoms, along with the PDE4 inhibitor.
Furthermore, the patent outlines specific PDE4 inhibitors that can be used in the treatment method, including theophylline, roflimilast, apremilast, ibdulast, GSK356278, or IBMX. Additionally, the method allows for the administration of various receptor agonists and hormone-based treatments, such as oxytocin receptor agonists, insulin, ghrelin, growth hormone-releasing hormone (GHRH), and Brain-derived neurotrophic factor (BDNF), among others. By combining the selective PDE4 inhibitor with other therapeutic agents, the method aims to address the complex array of symptoms associated with PWS, offering a comprehensive approach to managing the condition.
To know more about GlobalData’s detailed insights on Acadia Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
